Adaptimmune Therapeutics, which is developing cancer immunotherapies based on genetically engineered T-cell receptors, filed on Monday with the SEC to raise up to $150 million in an initial public offering. The Abingdon, United Kingdom-based company, which was founded in 2008 , plans to list on the NASDAQ under the symbol ADAP. Adaptimmune Therapeutics initially filed...read more
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, announced terms for its US offering on Wednesday. The Paris, France-based company plans to raise $129 million by offering 3.5 million ADSs. Its shares currently trade on the Alternext market of the Euronext Paris under the symbol ALCLS and its last share price was €35, or $36.83....read more
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s close on Friday, March 20, 2015: Additions: Juno Therapeutics Shell Midstream Partners LP Cnova N.V. Removals: Zoetis Norwegian Cruise Line Pinnacle Foods Bright...read more
Spark Therapeutics, which is developing gene therapy treatments for retinal dystrophies and hematologic disorders, announced terms for its IPO on Tuesday. The Philadelphia, PA-based company plans to raise $88 million by offering 5.5 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Spark Therapeutics would command a fully diluted market value of...read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Cancer immunotherapy biotech Adaptimmune Therapeutics files for a $150 million IPO
Adaptimmune Therapeutics, which is developing cancer immunotherapies based on genetically engineered T-cell receptors, filed on Monday with the SEC to raise up to $150 million in an initial public offering. The Abingdon, United Kingdom-based company, which was founded in 2008 , plans to list on the NASDAQ under the symbol ADAP. Adaptimmune Therapeutics initially filed...read more
Cancer biotech Cellectis sets terms for $129 million IPO
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, announced terms for its US offering on Wednesday. The Paris, France-based company plans to raise $129 million by offering 3.5 million ADSs. Its shares currently trade on the Alternext market of the Euronext Paris under the symbol ALCLS and its last share price was €35, or $36.83....read more
Renaissance IPO Index - Notice of March 2015 Quarterly Changes
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s close on Friday, March 20, 2015: Additions: Juno Therapeutics Shell Midstream Partners LP Cnova N.V. Removals: Zoetis Norwegian Cruise Line Pinnacle Foods Bright...read more
Gene therapy biotech Spark Therapeutics sets terms for $88 million IPO
Spark Therapeutics, which is developing gene therapy treatments for retinal dystrophies and hematologic disorders, announced terms for its IPO on Tuesday. The Philadelphia, PA-based company plans to raise $88 million by offering 5.5 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Spark Therapeutics would command a fully diluted market value of...read more